Cencora's Net Income Soars 45.5% on Strong Quarter

Cencora, Inc. reported robust financial results for its fiscal year 2025 third quarter, ended June 30, 2025. Revenue increased 8.7% year-over-year to $80.7 billion, while GAAP diluted earnings per share (EPS) surged by 45.5% to $3.52, significantly exceeding the prior year's $2.42. The company's revenue of $80.7 billion slightly missed the analyst estimate of $80.115 billion, but the GAAP diluted EPS of $3.52 exceeded the analyst estimate of $3.78 (which is typically an adjusted EPS estimate, though the filing only provided GAAP EPS for comparison to prior year). Adjusted diluted EPS also saw a substantial increase of 19.8%, reaching $4.00 compared to $3.34 in the prior-year quarter.

Key Performance Drivers

The strong performance was primarily driven by an 8.5% increase in revenue within the U.S. Healthcare Solutions segment and a 10.5% increase in the International Healthcare Solutions segment. The U.S. Healthcare Solutions segment's revenue growth was attributed to overall market expansion, including increased unit volume for GLP-1 class products (diabetes and weight loss) and specialty products for physician practices and health systems. The segment's operating income rose 29.1%, boosted by increased product sales and the January 2025 acquisition of Retina Consultants of America (RCA). Adjusted gross profit for the company increased 20.7%, reaching $2.9 billion, with an improved margin of 3.55%, up 36 basis points from the prior year, largely due to the RCA acquisition.

Management Commentary and Outlook

Robert P. Mauch, President and Chief Executive Officer of Cencora, highlighted the company's strong financial results, attributing them to its pharmaceutical-centric strategy and focus on growth priorities. Mauch emphasized the team's role in identifying opportunities and customer-centric solutions that enhance Cencora's value proposition. Strategic drivers include digital transformation, investment in talent and culture, prioritizing growth-oriented investments, and increasing productivity. Cencora has updated its fiscal year 2025 outlook, raising the adjusted diluted EPS guidance range to $15.85 to $16.00, up from the previous range of $15.70 to $15.95, primarily due to stronger earnings growth in the U.S. Healthcare Solutions segment. The company also anticipates revenue growth to be approximately 9% for the full fiscal year.

For fiscal year 2025, the company expects U.S. Healthcare Solutions segment revenue growth to be in the range of 9% to 10%, and International Healthcare Solutions segment revenue growth to be in the range of 6% to 7%. Adjusted consolidated operating income growth is projected to be between 15% and 16%, with U.S. Healthcare Solutions segment operating income growth estimated at 20% to 21%. The adjusted effective tax rate is anticipated to be in the range of 20.5% to 21%. The Board of Directors declared a quarterly cash dividend of $0.55 per common share, payable September 3, 2025.